Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Stomach Neoplasms 2Liver Neoplasms 2Weight Loss 1Primary Graft Dysfunction 1Peripheral Nervous System Diseases 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Muscular Atrophy 1Lymphoma, Non-Hodgkin 1Liver Failure, Acute 1Liver Failure 1Liver Diseases 1Hodgkin Disease 1Hearing Loss 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Bronchogenic 1

Interventions

Cyclophosphamide 7X-Rays 6Phantoms, Imaging 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Nuclear Medicine Department, Hospital 4Carboplatin 4fludarabine 3Temozolomide 3Nivolumab 3Gemcitabine 3Filgrastim 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2pembrolizumab 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2ensartinib 2belinostat 2Vemurafenib 2Topotecan 2Psychiatric Rehabilitation 2Oxaliplatin 2Mesna 2LY3023414 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × Acetylcysteine × Gastrointestinal × Clear all
NCT02094625 2023-04-18

NAC to Prevent Cisplatin-induced Hearing Loss

Children's Hospital Los Angeles

Phase 1 Completed
52 enrolled
GastrointestinalSarcoma

Liver Neoplasms, Osteosarcoma, Neuroectodermal Tumors, Primitive, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡